» Articles » PMID: 28408746

Novel Metrics to Measure Coverage in Whole Exome Sequencing Datasets Reveal Local and Global Non-uniformity

Overview
Journal Sci Rep
Specialty Science
Date 2017 Apr 15
PMID 28408746
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Whole Exome Sequencing (WES) is a powerful clinical diagnostic tool for discovering the genetic basis of many diseases. A major shortcoming of WES is uneven coverage of sequence reads over the exome targets contributing to many low coverage regions, which hinders accurate variant calling. In this study, we devised two novel metrics, Cohort Coverage Sparseness (CCS) and Unevenness (U) Scores for a detailed assessment of the distribution of coverage of sequence reads. Employing these metrics we revealed non-uniformity of coverage and low coverage regions in the WES data generated by three different platforms. This non-uniformity of coverage is both local (coverage of a given exon across different platforms) and global (coverage of all exons across the genome in the given platform). The low coverage regions encompassing functionally important genes were often associated with high GC content, repeat elements and segmental duplications. While a majority of the problems associated with WES are due to the limitations of the capture methods, further refinements in WES technologies have the potential to enhance its clinical applications.

Citing Articles

Comparison of next‑generation sequencing quality metrics and concordance in the detection of cancer‑specific molecular alterations between formalin‑fixed paraffin‑embedded and fresh‑frozen samples in comprehensive genomic profiling with the....

Loderer D, Hornakova A, Tobiasova K, Leskova K, Halasova E, Dankova Z Exp Ther Med. 2025; 29(4):64.

PMID: 39991725 PMC: 11843196. DOI: 10.3892/etm.2025.12814.


Comparative evaluation of four exome enrichment solutions in 2024: Agilent, Roche, Vazyme and Nanodigmbio.

Belova V, Vasiliadis I, Repinskaia Z, Samitova A, Shmitko A, Ponikarovskaya N BMC Genomics. 2025; 26(1):76.

PMID: 39871131 PMC: 11770928. DOI: 10.1186/s12864-024-11196-z.


Diagnostic yield of exome and genome sequencing after non-diagnostic multi-gene panels in patients with single-system diseases.

Wilke M, Klee E, Dhamija R, Fervenza F, Thomas B, Leung N Orphanet J Rare Dis. 2024; 19(1):216.

PMID: 38790019 PMC: 11127317. DOI: 10.1186/s13023-024-03213-x.


Drug development advances in human genetics-based targets.

Zhang X, Yu W, Li Y, Wang A, Cao H, Fu Y MedComm (2020). 2024; 5(2):e481.

PMID: 38344397 PMC: 10857782. DOI: 10.1002/mco2.481.


Application of single-cell sequencing to the research of tumor microenvironment.

Chen S, Zhou Z, Li Y, Du Y, Chen G Front Immunol. 2023; 14:1285540.

PMID: 37965341 PMC: 10641410. DOI: 10.3389/fimmu.2023.1285540.


References
1.
Kane M, Jatkoe T, Stumpf C, Lu J, Thomas J, Madore S . Assessment of the sensitivity and specificity of oligonucleotide (50mer) microarrays. Nucleic Acids Res. 2000; 28(22):4552-7. PMC: 113865. DOI: 10.1093/nar/28.22.4552. View

2.
Clark M, Chen R, Lam H, Karczewski K, Chen R, Euskirchen G . Performance comparison of exome DNA sequencing technologies. Nat Biotechnol. 2011; 29(10):908-14. PMC: 4127531. DOI: 10.1038/nbt.1975. View

3.
Berg J . Genome-scale sequencing in clinical care: establishing molecular diagnoses and measuring value. JAMA. 2014; 312(18):1865-7. DOI: 10.1001/jama.2014.14665. View

4.
Pruitt K, Tatusova T, Klimke W, Maglott D . NCBI Reference Sequences: current status, policy and new initiatives. Nucleic Acids Res. 2008; 37(Database issue):D32-6. PMC: 2686572. DOI: 10.1093/nar/gkn721. View

5.
Williams T . Human leukocyte antigen gene polymorphism and the histocompatibility laboratory. J Mol Diagn. 2001; 3(3):98-104. PMC: 1906958. DOI: 10.1016/S1525-1578(10)60658-7. View